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Abstract
Using DNA microarrays, we generated both mRNA and miRNA expression data from 6 non-small cell lung cancer (NSCLC)
tissues and their matching normal control from adjacent tissues to identify potential miRNA markers for diagnostics. We
demonstrated that hsa-miR-96 is significantly and consistently up-regulated in all 6 NSCLCs. We validated this result in an
independent set of 35 paired tumors and their adjacent normal tissues, as well as their sera that are collected before surgical
resection or chemotherapy, and the results suggested thathsa-miR-96 may play an important role in NSCLC development and
has great potential to be used as a noninvasive marker for diagnosing NSCLC. We predicted potential miRNA target mRNAs
based on different methods (TargetScan and miRanda). Further classification of miRNA regulated genes based on their
relationship with miRNAs revealed that hsa-miR-96 and certain other miRNAs tend to down-regulate their target mRNAs in
NSCLC development, which have expression levels permissive to direct interaction between miRNAs and their target mRNAs.
In addition, we identified a significant correlation of miRNA regulation with genes coincide with high density of CpG islands,
which suggests that miRNA may represent a primary regulatory mechanism governing basic cellular functions and cell
differentiations, andsuch mechanism maybecomplementary toDNAmethylation inrepressing or activatinggeneexpression.
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Introduction
Currently, non-small cell lung cancer (NSCLC) is the leading
cause of cancer death in the world[1]. Surgical resection is mainly
performed in early-stage cases and is also effective, but its effect is
limited for patients with locally advanced cancers because of the
high rate of distant metastasis and recurrence. Thus, chemother-
apy and radiation therapy, as well as a combination of both, are
always performed in the treatment of patients with locally
advanced cancers. However, the 5-year survival rate of lung
cancer patients decreases dramatically with clinical stages of the
disease, for instance, from an estimated 61% for patients with the
stage IA disease to 38% for patients with the stage IB disease.
Other stage-related 5-year survival rate of the disease are 34% for
patients with IIA disease, 13% for patients with stage IIIA disease,
5% for patients with stage IIIB disease, and 1% for patients with
stage IV [2,3,4,5]. Most lung cancer patients are only diagnosed
after tumors have spread beyond their primary sites, and this is an
important reason for the poor outcome of lung cancer treatments.
In addition, variation analysis among a variety of cancers
suggested that lung cancer has larger number of mutated genes
than other cancers [6]. Therefore, the discovery of effective
diagnostic markers and interrogating mechanisms of lung cancer
development, are both necessary for improving the survival rate of
lung cancer patients.
miRNAs are short non-coding RNAs (,22 nt long) that bind
complementary sequences in target mRNAs, resulting in their
selective degradation or selective inhibition of translation. There-
fore, through regulating their target genes, miRNAs are known to
be involved in a wide range of biological functions, such as cellular
proliferation, differentiation, and apoptosis [7,8]. Aberrant miR-
NAs expression has been reported to cause diseases, such as cancers
[9], Alzheimer’s disease [10], heart diseases [11], spinal motor
neuron anomalies [12], and etc.. In NSCLC, it has been suggested
that miR-31 may act as an oncogenic miRNA by repressing tumor
suppressors: LATS2 and PPP2R2A [13], and expression of hsa-
miR-205 has been suggested to be able to distinguish squamous
from nonsquamousnon-small-celllung carcinoma[14].Inaddition,
evidences show that high hsa-mir-155 and low hsa-let-7a-2
expression correlated with poor survival of lung cancer patients
[15], and has-miRNA-126 may promote NSCLC cells apoptosis
induced by irradiation through the PI3K-Akt pathway [16].
miRNAs are now emerging as highly tissue-specific biomarkers
for discriminate cancers from noncancerous tissue, and different
cancer types, as well as different prognostic results [15,17].
mRNA profiling have revealed that transcriptional abnormality
of many genes are responsible for the development of NSCLC
[18,19], and differential expression of miRNAs also have been
detected between lung cancer tissues and the adjacent normal
tissues [15,20]. In the present study, we used microarrays to
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neously in paired NSCLC and their adjacent normal tissues to
investigate possible roles of miRNAs. Our analyses are both
integrated and rather deep in search for possible candidate
miRNAs and their mRNA targets for further investigations and
clinical applications.
Results
Differentially expressed mRNAs in NSCLC tissues
compared with their paired normal tissues
We performed gene expression profiling for paired tumor-
normal tissue samples from 6 NSCLC patients and investigated
34,694 genes/transcripts. We defined 581 up-regulated genes and
1, 297 down-regulated genes which were consistently up- or down-
regulated in all 6 tumor tissues compared with the adjacent normal
tissues (Table S2 and Table S3). Among differentially expressed
genes, we identified 2 significantly up-regulated and 22 signifi-
cantly down-regulated genes at a False Discovery Rate (FDR) of
0.1 (Table S2 and Table S3). We subsequently performed GO
enrichment analysis using hypergeometric test and multiple test
adjustment method BH through WebGestalt2 [21] and defined
the enriched pathways at a p value of ,0.001. The hypergeo-
metric distribution is a discrete probability distribution that
describes the number of successes in a sequence of n draws from
a finite population without replacement, just as the binomial
distribution describes the number of successes for draws with
replacement. Hypergeometric test helps to find which GO terms
are overrepresented in a large gene list. According to hypergeo-
metric test results, the cell cycle M-phase and DNA metabolic
process were predominantly activated, whereas pathways involved
in immune functions were significantly repressed in NSCLC
(Table 1). In addition, up-regulated genes were predominantly
enriched in ‘‘chromosome’’ as opposed to down-regulated genes
that were predominantly enriched in ‘‘cell membrane’’ (Table 2).
Differentially expressed miRNAs in NSCLC tissues
compared with their paired normal tissues
We performed miRNA expression profiling using the same 6
paired samples of the primary tumor and its adjacent normal
tissue. We obtained 25 up-regulated and 24 down-regulated
miRNAs which were consistently up- or down-regulated in all 6
tumor tissues compared with the adjacent normal tissues before
significance test (Table S4 and Table S5). Based on a more
Table 1. Enriched GO terms for biological process based on variable genes in lung cancer tissues when compared with their
adjacent normal tissues.
Class GO terms GO number Statistic*
Up-regulated DNA metabolic process GO:0006259 C=552;O=27;E=9.68;R=2.79;rawP=1.48e-06;adjP=0.0008
Up-regulated M phase GO:0000279 C=370;O=21;E=6.49;R=3.24;rawP=2.35e-06;adjP=0.0008
down-regulated immune response GO:0006955 C=750;O=101;E=42.54;R=2.37;rawP=1.51e-16;adjP=2.91e-13
down-regulated immune system process GO:0002376 C=1066;O=124;E=60.46;R=2.05;rawP=3.98e-15;adjP=3.84e-12
down-regulated defense response GO:0006952 C=657;O=89;E=37.26;R=2.39;rawP=8.14e-15;adjP=5.23e-12
down-regulated inflammatory response GO:0006954 C=359;O=60;E=20.36;R=2.95;rawP=2.82e-14;adjP=1.36e-11
down-regulated response to wounding GO:0009611 C=560;O=75;E=31.76;R=2.36;rawP=2.23e-12;adjP=8.60e-10
down-regulated response to stress GO:0006950 C=1696;O=147;E=96.19;R=1.53;rawP=5.52e-08;adjP=1.33e-05
down-regulated innate immune response GO:0045087 C=176;O=30;E=9.98;R=3.01;rawP=5.52e-08;adjP=1.33e-05
down-regulated response to external stimulus GO:0009605 C=904;O=91;E=51.27;R=1.77;rawP=4.51e-08;adjP=1.33e-05
down-regulated immune effector process GO:0002252 C=200;O=31;E=11.34;R=2.73;rawP=3.06e-07;adjP=6.56e-05
down-regulated regulation of immune system process GO:0002682 C=362;O=45;E=20.53;R=2.19;rawP=5.72e-07;adjP=0.0001
down-regulated leukocyte mediated immunity GO:0002443 C=126;O=22;E=7.15;R=3.08;rawP=2.14e-06;adjP=0.0002
down-regulated actin cytoskeleton organization GO:0030036 C=257;O=35;E=14.58;R=2.40;rawP=1.28e-06;adjP=0.0002
down-regulated positive regulation of immune
system process
GO:0002684 C=229;O=32;E=12.99;R=2.46;rawP=2.08e-06;adjP=0.0002
down-regulated lymphocyte activation GO:0046649 C=272;O=36;E=15.43;R=2.33;rawP=1.80e-06;adjP=0.0002
down-regulated T cell activation GO:0042110 C=194;O=29;E=11.00;R=2.64;rawP=1.57e-06;adjP=0.0002
down-regulated leukocyte activation GO:0045321 C=324;O=41;E=18.38;R=2.23;rawP=1.15e-06;adjP=0.0002
down-regulated actin filament-based process GO:0030029 C=274;O=36;E=15.54;R=2.32;rawP=2.14e-06;adjP=0.0002
down-regulated adaptive immune response GO:0002250 C=113;O=20;E=6.41;R=3.12;rawP=4.97e-06;adjP=0.0005
down-regulated adaptive immune response based
on somatic recombination of immune
receptors built from immunoglobulin
superfamily domains
GO:0002460 C=112;O=20;E=6.35;R=3.15;rawP=4.31e-06;adjP=0.0005
down-regulated lymphocyte mediated immunity GO:0002449 C=106;O=19;E=6.01;R=3.16;rawP=7.04e-06;adjP=0.0007
down-regulated positive regulation of biological
process
GO:0048518 C=1865;O=148;E=105.77;R=1.40;rawP=9.03e-06;adjP=0.0008
down-regulated cell activation GO:0001775 C=366;O=42;E=20.76;R=2.02;rawP=1.05e-05;adjP=0.0009
*The alst column lists the number of reference genes in the category (C), number of genes in the gene set and also in the category (O), expected number in the category
(E), Ratio of enrichment (R), p value from hypergeometric test (rawP), and p value adjusted by the multiple test adjustment (adjP).
doi:10.1371/journal.pone.0026502.t001
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miRNA, hsa-miR-96, at a False Discovery Rate (FDR) of 0.1. We
further examined the expression level of its potential mRNA
targets (These targets have conserved miRNA binding sites among
vertebrates or mammals and were predicted using TargetScan): 13
out of 728 total candidate target genes (Table S2 and Table S6)
(account for 2.24% of the 581 up-regulated genes) were up-
regulated and 48 out of the total (Table S3 and Table S6) (account
for 3.70% of the 1, 297 down-regulated genes) were down-
regulated (Figure 1A). We then validated hsa-miR-96 expression
based on quantitative RT-PCR in an independent set of 35
NSCLC and their serum samples (for the sera, expression values
were normalized to normal people without cancer history or other
illness at that time), and found hsa-miR-96 was significantly up-
regulated in both tissue and serum samples from NSCLC patients
(Figure 2). Therefore, hsa-miR-96 may be an important factor to
contribute to NSCLC development and may have great potential
to be used for diagnosing.
As miRNAs always repress the expression of the target genes,
the 48 down-regulated targets of hsa-miR-96 may be most likely
to contribute to NSCLC development through hsa-miR-96
regulation. We selected 10 down-regulated targets of hsa-miR-
96 to validate their mRNA expression levels using qRT-PCR in
20 NSCLC and found that all of them were significantly down-
regulated in tumor tissues when compared with the adjacent
normal tissues (Figure 1B). To investigate how these 48 down-
regulated potential mRNA targets may affect the development
of NSCLC, we classified them based on GO terms, and found
that these genes were involved in a variety of basic biological
process, including metabolism, biological regulation, cell
communication, developmental process, immune system, and
etc. (Figure S2).
Classification of mRNAs based on their relationship with
miRNA regulation
To characterize how miRNAs may regulate their target
mRNAs, we performed an extensive analysis on the correlated
expression of miRNAs and their target mRNAs. miRNAs are
expressed as long precursor RNAs that are processed by a cellular
nuclease, Drosha, before being transported by an Exportin-5-
dependent mechanism into the cytoplasm [22,23]. Once in the
cytoplasm, miRNAs are cleaved further by the enzyme DICER
[24,25], and this results in 17–24 nt miRNAs that are associated
with a cellular complex that is similar to the RNA-induced
silencing complex that participates in RNA interference. However,
miRNAs mainly regulate mRNA translation, whereas siRNAs
direct RNA destruction via the RNA interference (RNAi) pathway
[8,26]. Therefore, the abundance of miRNAs may mainly depend
on its original expression and not imported exogenously. In
addition, several lines of evidence suggest that elevation of miRNA
expression lead to down-regulation of the target genes, and
reduction of miRNA expression lead to up-regulation of the target
genes [13,27]. We therefore hypothesize that the effect of miRNAs
on their target mRNAs is expression level-dependent. We used a
Table 2. Enriched GO terms for cellular components based on variable genes in lung cancer tissues when compared with their
adjacent normal tissues.
Class GO terms GO number Statistic*
Up-regulated chromosome GO:0005694 C=454;O=26;E=8.45;R=3.08;rawP=3.99e-
07;adjP=5.35e-05
Up-regulated chromosomal part GO:0044427 C=378;O=23;E=7.03;R=3.27;rawP=6.77e-
07;adjP=5.35e-05
Up-regulated chromosome, centromeric region GO:0000775 C=120;O=11;E=2.23;R=4.93;rawP=1.48e-
05;adjP=0.0008
Down-regulated plasma membrane part GO:0044459 C=1918;O=169;E=104.66;R=1.61;rawP=7.90e-
11;adjP=2.21e-08
Down-regulated integral to plasma membrane GO:0005887 C=1183;O=112;E=64.55;R=1.74;rawP=4.46e-
09;adjP=6.24e-07
Down-regulated plasma membrane GO:0005886 C=3650;O=269;E=199.17;R=1.35;rawP=1.34e-
08;adjP=9.38e-07
Down-regulated intrinsic to plasma membrane GO:0031226 C=1206;O=112;E=65.81;R=1.70;rawP=1.30e-
08;adjP=9.38e-07
Down-regulated membrane part GO:0044425 C=6381;O=417;E=348.19;R=1.20;rawP=7.79e-
07;adjP=3.64e-05
Down-regulated membrane GO:0016020 C=7186;O=462;E=392.12;R=1.18;rawP=7.05e-
07;adjP=3.64e-05
Down-regulated I-kappaB/NF-kappaB complex GO:0033256 C=4;O=4;E=0.22;R=18.33;rawP=8.81e-06;adjP=0.0004
Down-regulated lytic vacuole GO:0000323 C=206;O=27;E=11.24;R=2.40;rawP=2.13e-
05;adjP=0.0006
Down-regulated intrinsic to membrane GO:0031224 C=5451;O=355;E=297.44;R=1.19;rawP=1.80e-
05;adjP=0.0006
Down-regulated lysosome GO:0005764 C=206;O=27;E=11.24;R=2.40;rawP=2.13e-
05;adjP=0.0006
Down-regulated cell-substrate adherens junction GO:0005924 C=100;O=17;E=5.46;R=3.12;rawP=2.67e-
05;adjP=0.0007
*The last column lists the number of reference genes in the category (C), number of genes in the gene set and also in the category (O), expected number in the category
(E), Ratio of enrichment (R), p value from hypergeometric test (rawP), and p value adjusted based on the multiple test adjustment (adjP).
doi:10.1371/journal.pone.0026502.t002
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value. We first assume that a regulation value of a miRNA is
positively correlated with its expression level. Since a miRNA
always has more than one target genes [28], we then assume that a
regulation value of a given miRNA is negatively correlated with
the number of its targets. Therefore, we define a regulation value
for miRNA as the deviation in expression level for a given miRNA
divided by the number of expressed mRNA targets.
During cancer development, the regulation may vary from case
to control for a given miRNA and, therefore, regulation value of a
given miRNA equals to the variation of miRNA expression
divided by the number of expressed targets. When the expression
of a miRNA is down-regulated in cancers, its regulation value
becomes negative if the number of its expressed targets is not
changed significantly. For a target mRNA, its regulation value is
the sum of all regulation values from its regulatory miRNA. Based
on these definitions, we classified all differentially expressed genes
in cancers into different groups based on their correlations—
correlated or anti-correlated with miRNA regulation. Before doing
this, we predicted the potential target genes of these consistently
up- or down-regulated miRNAs.
We used three methods to predict the potential targets of
miRNAs. The software TargetScan focuses more on miRNA seed
(2-8nt in the 59 region of mature miRNA), as evidence suggests the
importance of this region for miRNA target recognition
[29,30,31,32]. In addition, the sequence conservation of target
sites has been considered as an important feature to reduce false-
positive rate [30]. We therefore predicted potential miRNA targets
using TargetScan and conserved target sites among vertebrates or
mammals using PCT method of TargetScan [33]. However, seed
sites do not always confer repression, and the software miRanda
also takes into consideration of other region of miRNA in addition
to seed sites [34]. We then used miRanda as another alternative
method to predict miRNA targets. The two software were
frequently used to predict miRNA targets, and in addition, both
of them can be used to predict targets of novel miRNAs as the
illuminia miRNA microarray "humanMI_V2" contains many
novel miRNAs that are generated from next-generation sequenc-
ing efforts worldwide. We obtained 16,160 conserved miRNA-
Figure 1. Down-regulated target candidates of hsa-miR-96 in
NSCLC. (A) Microarray results of the Down-regulated target candidates
of hsa-miR-96 in NSCLC. We assayed 6 paired NSCLC vs. normal tissue. C
and N stand for cancer and adjacent normal tissue, respectively. The
asterisk marks genes belong to the correlated group and the remaining
genes are grouped into the anti-correlated group according to the
expression relationship of these genes with their regulatory miRNAs. (B)
Validation of microarray results by qRT-PCR. We selected 10 down-
regulated target candidates of hsa-miR-96 and performed qRT-PCR
experiments for the validation of relative mRNA expression in reference
to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The relative
expression values are the means 6 SE. *, P,0.05 by t test; **, P,0.001
by t test.
doi:10.1371/journal.pone.0026502.g001
Figure 2. Quantitative RT-PCR analysis of hsa-miR-96 expres-
sion. Two groups of comparisons were performed: (1) tumor vs.
adjacent normal lung tissues, and (2) cancer serum vs. non-cancer
serum. Relative hsa-miR-96 expression was determined in reference to
an internal U6 snRNA control. Relative expression values are the
normalized mean 6 SE.
doi:10.1371/journal.pone.0026502.g002
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TargetScan (Table S6), 70,320 miRNA-target pairs by using
TargetScan without considering the conservation condition (Table
S8), and 77,988 miRNA-target pairs by using miRanda (Table
S10). We observed that 48,841 miRNA-target pairs were present
in both TargetScan and miRanda results (69.46% of TargetScan
results, 62.63% of miRanda results), and 12,403 miRNA-target
pairs of conserved TargetScan results were common with
miRanda results (76.75% of conserved TargetScan results).
Therefore, there were about 70% prediction results that were
common in the two different methods, and conserved prediction
results of TargetScan exhibite a larger proportion of shared genes.
We firstly used the conserved prediction results to classify
mRNAs based on their relationship with miRNA regulation. In
particular, we defined 197 and 190 genes as anti-correlated and
correlated, respectively, and 1,491 as ‘‘others’’, whose miRNA
regulation values are null (Table S7). We further investigated the
distribution of miRNA regulation value, gene expression level and
the potential relationship between these two parameters. In the 197
anti-correlated genes, 171 (account for 13.18% of 1, 297 down-
regulated genes) were down-regulated and 26 (account for 4.48% of
581 up-regulated genes) were up-regulated. Gene distribution based
on the regulation value also suggested that the anti-correlated group
were always down-regulated by miRNAs (Figure 3A). In the 190
correlated genes, 140 (account for 10.79% of 1, 297 down-regulated
genes) were down-regulated and 50 (account for 8.61% of 581 up-
regulated genes) were up-regulated. Gene distribution based on the
regulation value suggested that the correlated group were always
Figure 3. miRNA regulation analysis. We classified all expression-variable mRNAs during lung cancer development based on their relationship
with miRNAs. The results are classified into correlated, anti-correlated, and others (no correlation). The correlated mRNAs show correlated expressions
to their regulatory miRNA expressions and the anti-correlated mRNAs are not. Three different methods were used to predict potential miRNA targets:
‘‘Conserved’’ are those genes that have conserved miRNA binding sites among vertebrates or mammals, and these genes were predicted by using
the PCT method of TargetScan; ‘‘TargetScan’’ are those genes that are predicted by using a perl script of TargetScan without considering conservation.
‘‘miRanda’’ are those genes that are predicted potential targets based on miRanda v3.3a on Linux platform. (A) Gene distribution of the correlated
and anti-correlated mRNAs was plotted based on their miRNA regulation values. (B) Gene distribution of the three groups of mRNAs was plotted
based on their expression values. The expression value was defined by referencing that of the adjacent normal tissue (log2). (C) The relationship
between gene expression and miRNA regulation.
doi:10.1371/journal.pone.0026502.g003
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(account for 76.02% of 1,297 down-regulated genes) were down-
regulated and 505 (account for 86.92% of 581 up-regulated genes)
were up-regulated (Table 3). In conclusion, these results indicate
that miRNAs tend to down-regulate gene expression, especially for
those of the anti-correlated group. We also investigated potential
functions of the anti-correlated group, which were supposed to be
regulated by miRNAs, and found they were involved in a variety of
biological processes, including metabolism, immune systems, cell
killing, multicellular organismal development, and cell communi-
cation (Figure S3).
We further verified this result using predictions of TargetScan
without considering sequence conservation and predictions of
miRanda. Using miRanda, we have 482 and 294 genes as anti-
correlated and correlated, respectively, and 1,102 as ‘‘others’’.
Using TargetScan without considering conservation, we have 472
and 285 genes as the anti-correlated and correlated, respectively,
and 1,121 as ‘‘others’’. We further investigated the intersection
between TargetScan and miRanda, and found that the three
methods shared about 80% in the anti-correlated group;
TargetScan and miRanda shared about 70% genes in the
correlated group, while PCT method shared only about 50%
genes with the remaining two methods in the correlated group.
Consistent with the results of conserved predictions, miRNAs in
the anti-correlated group seem regulate higher proportion of
down-regulated mRNAs as compared to the remaining groups
defined based on the following two methods (Table 3), and the
anti-correlated group exhibited strikingly different distribution of
regulation value as compared to the correlated group (Figure 3A).
We then examined target expression level of the three
regulation groups and found that expression level of the anti-
correlated group was higher than the remaining groups
(Figure 3B). Further investigation of regulation values with the
expression level showed that highly-expressed genes in the anti-
correlated group tended to be down-regulated by miRNAs,
whereas lowly-expressed genes tended to be up-regulated. Genes
in the correlated group behave in the opposite way (Figure 3C).
This result suggested that highly expressed genes may contribute
more to down-regulated genes in anti-correlated group than to up-
regulated genes in the same group.
Potential relationship of miRNAs with methylation in
regulating mRNA expression
As methylation is another important mechanism to regulate
mRNA expression, we further studied how it may interact with
miRNA regulation. We first categorized the target genes into
HCG (high CpG content), LCG (intermediate CpG content), and
ICG (low CpG content) classes (Table S2 and Table S3) according
a method previously described [35]. We found that in the
conserved prediction results, both the anti-correlated and
correlated groups contained more HCG genes than others or all
genes (Figure 4A), and the result suggests that HCG genes are
most likely to be regulated by miRNAs that have conserved target
sites.
Since a large number of highly-expressed genes were found in
the anti-correlated group, we further asked if these HCG genes are
always highly-expressed and tend to miRNA-regulated. In all
genes expressed in NSCLC, HCG genes were not seen as
dominant in highly expressed genes as compared to LCG or ICG
genes. The peak expressions of HCG range from 5 to 10, whereas
those of ICG or LCG genes are in a range of 2 to 7. miRNA tends
to regulate more genes at the relative expression level of 5 to 10,
therefore, when regulated by miRNAs, the peak of ICG or LCG
gene expressions should be in this range, and we observed that
there were less LCG genes in this expression range as compared to
HCG or ICG genes. However, ‘‘others’’ (genes with no regulation
value variation) also has a peak in the expression range but there
was no difference in gene density among the three CpG classes
(Figure 4B). In summary, HCG genes may be enriched genes that
are regulated by miRNAs due to their high expression levels, but
this is obviously not the only reason.
We also performed GO analysis between the miRNA-regulated
and miRNA-insensitive groups to show that their genes and
functions are different from the anti-correlated and the correlated
groups (Figure 5 and Figure S5). As it is shown in Figure 5, the
miRNA-regulated group contains more genes in the following
processes: transcription regulation, nucleic acid binding, cell
communication, metabolic, and development regulation. These
differences demonstrate from another angle why miRNAs tend to
affect HCG genes with conserved miRNA target sites as CpG
island content is always correlated with gene regulation and
functional differentiation, and these genes may be of importance
for basic cellular functions of different vertebrates or mammals
[36].
Discussion
In this study, we investigated the mRNA and miRNA profiling
of NSCLC. mRNA profiling revealed that a number of
differentially-expressed genes are involved in activation of cell
Table 3. Three groups of mRNAs predicted with different methods.
miRanda* TargetScan* Conserved*
Anti-correlated All 482 472 197
Up-regulated 53(9.12%) 55(9.47%) 26(4.48%)
Down-regulated 429(33.08%) 417(32.15%) 171(13.18%)
Correlated All 294 285 190
Up-regulated 117(20.14%) 108(18.59%) 50(8.61%)
Down-regulated 177(13.65%) 177(13.65%) 140(10.97%)
Others All 1102 1121 1491
Up-regulated 411(70.74%) 418(71.94%) 505(86.92%)
Down-regulated 691(53.28%) 703(54.2%) 986(76.02%)
*The proportion was calculated by dividing the number of all up-regulated mRNAs or down-regulated mRNAs.
doi:10.1371/journal.pone.0026502.t003
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studies, which suggest that abnormal cell cycle is associated with
elevated lung cancer risk [37,38]. The down-regulated genes are
found to be predominantly enriched in immune systems as well as
those localized on cell membranes, which are usually correlated
with cell-cell communication and participate in immune process.
Inhibitions of these genes have been supposed to facilitate lung
cancer development and progression, and this may to some extent
due to the escape of cancer cells from detection and destruction by
the host immune system [39,40,41].
In miRNA profiling comparison, we found hsa-miR-96 was
significantly up-regulated in NSCLC. 48 hsa-miR-96 potential
targets were predominantly enriched in the down-regulated
mRNA group and are involved in a variety of biological processes
according to GO annotations. Based on regulation value estimates,
we showed that 42 of them belong to the anti-correlated group
(Figure 1A, Table S7). Our validation experiments revealed that
the mature form of hsa-miR-96 is highly expressed not only in
cancer tissues but also in sera of cancer patients. This result
suggests that hsa-miR-96 has a great potential to be used as a
noninvasive biomarker for NSCLC diagnosis.
Our current knowledge about hsa-miR-96 is rather limited. It
resides in the intergenic area between NRF1 and UBE2H on
human chromosome 7 [42] and has a very broad distribution
among animals, from nematodes to mammals, and is more
conserved among vertebrates (Figure S4). Previous studies have
suggested that it functions to regulate the progression of
differentiation in mammalian cochlear inner and outer hair cells
[43], and is associated with aggressive human behaviors [44]. In
the relationship with cancers, hsa-miR-96 has been reported to be
highly expressed in bladder cancer [45], prostate carcinoma [46],
and chronic myeloid leukemia [47]. It can be detected in urine
and is correlated with stage and grade based on urinary cytology of
urothelial carcinoma [48]. Up-regulation of hsa-miR-96 results in
down-regulations of transcriptional factor FOXO3a and FOXO1,
and thus induces cell proliferation in human breast cancer [49,50].
In our assays, we found a set of potential targets that may correlate
with the function of hsa-miR-96 in NSCLC development, but
none of the potential targets have been validated by experiments.
Therefore, further experimentation is of essence in revealing
relationship between hsa-miR-96 and NSCLC. In addition, we
will increase the size of the specimen to investigate possible
relationship of hsa-miR-96 expression with prognosis, and other
characteristics of NSCLC.
In General, miRNAs are believed to bind the 39 untranslated
region of a target mRNA and down-regulate its expression at
Figure 4. Potential relationship between miRNA and DNA methylation. (A) The distribution of CpG-density classified genes in each group.
These target genes were predicted using three different methods: ‘‘Conserved’’ are those genes that have conserved miRNA binding sites among
vertebrates or mammals, and these genes were predicted by using the PCT method of TargetScan; ‘‘TargetScan’’ are those genes that are predicted by
using a perl script of TargetScan without considering conservation. ‘‘miRanda’’ are those genes that are predicted potential targets based on miRanda
v3.3a on Linux platform. (B) Relationship between CpG island density and gene expression. Three groups were classified: all expressed genes in
NSCLC, the miRNA-regulated genes, and other genes which may not be influenced by miRNAs.
doi:10.1371/journal.pone.0026502.g004
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Therefore, when the expression of a miRNA is elevated, mRNAs
that are regulated by the miRNA is expected to be down-
regulated; when the expression of miRNA is repressed, its target
mRNAs should show up-regulations. However, according to our
results, the anti-correlated mRNAs are always down-regulated and
only a small fraction of genes are up-regulated. Further
examination suggested that in the anti-correlated group, down-
regulated mRNAs are always highly expressed, and up-regulated
mRNAs are always lowly expressed. Therefore, the existence of
more highly expressed genes may be an important contributor to
the effect. The reason why highly-expressed mRNAs tend to be
down-regulated by miRNAs and the lowly-expressed mRNAs tend
to be up-regulated by miRNAs suggests an existence of a
regulatory balance that functions to keep the entire transcriptome
in an optimized dynamic range.
In our analysis, we failed to find any clues that are responsible
for the difference between the anti-correlate and the correlated
mRNAs. GO classification did not show any obvious difference
either (Figure S5). In addition, expression levels of the target
mRNAs that have a high regulation value did not show significant
variation, and vice versa (Table S2, Table S3,Table S7, Table S9,
Table S11), and genes whose expression are significantly varied
are not necessarily significantly regulated. Since a mRNA is often
regulated by more than one miRNAs [28], we are still unable to
know how these miRNAs interact with one another, and which
kind of direct interactions are most effective. Furthermore,
miRNAs may repress their target genes only at the protein level
[52] and the targets may not exhibit noticeable changes at the
mRNA level. There are other factors that are involved in
regulating mRNAs at epigenetic levels, such as histone methyla-
tion [53,54] and acetylation [55,56], and that are always capable
of interfering with miRNA-centric networks [57,58], making
deciphering such networks more difficult.
Another interesting observation is that genes in either the
correlated group or the anti-correlated group have a larger
proportion of HCG genes than that in ‘‘others’’ group. Both the
correlated and the anti-correlated groups are considered most
likely to be influenced or possibly regulated by miRNAs. This
result suggests that miRNAs tend to regulate HCG genes. Further
investigation demonstrated that HCG genes tended to express at a
higher level when compared with ICG or LCG genes. Therefore,
there may be a possibility that more HCG genes are influenced by
miRNAs. However, comparisons based on all potential targets
failed to show any difference among these groups (Figure 4A). As
the stringent standard selected targets have conserved binding sites
of miRNAs among vertebrates or mammals, more HCG target
genes in miRNA-influenced group may correlate with gene
evolution among vertebrates.
GO comparison between the regulated and the unregulated
groups demonstrated they were quite different as the former
always contains more genes involved in transcription regulation,
nucleic acid binding, cell communication, metabolic, and
development regulation. The function of genes and their
expression is always correlated with the CpG island content of
promoters. It has been suggested that house-keeping functions are
significantly overrepresented in the HCG class, whereas terms
associated with specific functions characteristic of more differen-
tiated or highly regulated cells are significantly overrepresented in
the LCG class [36,59]. miRNA has been proposed to be a primary
regulation mechanism as it is present from low to high organisms,
it therefore may prefer to regulate a higher proportion of HCG
genes for basic cellular functions. These are possible reasons why
miRNA regulation may be more biased toward HCG genes.
DNA methylation plays a role in the repression of gene
expression in animal cells, but in many cells, most genes are
inactive even their CpG island-containing promoters remain
unmethylated [35,60]. This implies that there may be other
regulatory mechanisms involved, such as histone modifications
and miRNAs. Inactive HCG genes were more frequently
unmathylated as compared with ICG or LCG genes, and it was
most likely that the role of enriched demethylated H3K4 is to
Figure 5. Different GO terms between the miRNA-regulated and miRNA-unregulated genes. P,0.05 was considered as significant [67].
doi:10.1371/journal.pone.0026502.g005
Integrated RNA Analysis of NSCLC
PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e26502protect CpG islands from methylation [35]. In addition, a broad
H3 hyperacetylation in CpG islands has been reported [61].
Therefore, histone modifications are most likely to affect DNA
methylation regulated gene repression, and an increasing number
of evidence has confirmed this conclusion [62,63]. Lung cancer
development is closely correlated with three most studied
epigenetic phenomena including modifications in DNA and
histone proteins as well as miRNAs [64]. The interaction between
DNA methylation and histone modification have been well studied
[65], while the relationship between DNA methylation and
miRNAs or miRNAs and histone modification has not been
elucidated. According to our results, there may be a possibility that
miRNAs play a role in bridging DNA methylation repression and
histone modifications.
Materials and Methods
Ethics Statement
All samples were obtained from the tissue bank of Zhoushan
Hospital (city of Zhoushan, Zhejiang province, China), which
assures written informed consent from all subjects. The Institu-
tional Review Board of Zhoushan Hospital approved the use of
samples for this study.
Patients and RNA extraction
We performed miRNA microarray and mRNA microarray
using 3 adenocarcinomas and 3 squamous cell carcinomas of the
lung as well as the paired control samples from their adjacent
normal tissues, which were carefully diagnosed and pathologically
defined (Table S1). Specimens were brought to pathologists
immediately for diagnosis (Figure S1). Tumor tissues and the
corresponding adjacent normal tissues were placed in different
tubes in liquid nitrogen and subsequently stored at -180uC. The
Total RNA that was used to perform microarray analysis was
extracted using TRIZOL (Invitrogen).
Since we used 3 adenocarcinomas (and controls) and 3
squamous cell carcinomas (and controls) of the lung for the
microarray analysis, we chose a comparable number of corre-
sponding NSCLC cases for validation. We also took into
consideration of the coverage of different genders, cancer stages,
ages, and other characteristics. In particular, we performed tissue
qRT-PCR validation using 35 pair specimens (17 paired samples
of adenocarcinomas and 18 paired samples of squamous cell
carcinomas of the lung), and further examined miRNA expression
abundance in the serum samples from the same 35 specimens.
There are 17 patients whose ages are more than 60 and 18
younger than 60 (including 7 males and 28 females). As for the
grade of differentiation, the tumors are 13 well differentiated, 18
moderately differentiated, and 4 are poorly differentiated. The
tumor stages are also clearly defined: 28 are at T1-T2 and 7 are in
T3-T4. In addition, lymph node metastases were found in 15
patients (8 patients are at stage I and 17 patients are higher stages;
Table S1). We collected the sera before surgical resection and
chemotherapy. We selected 20 people (9 males and 11 females; all
aged below 60) without any cancer histories and other illness and
collected their sera as normal controls. Total RNA including
miRNA from the tissue and serum samples were extracted by
using a commercial kit (mirVana RNA
TM Isolation kit, Applied
Biosystems) according to the supplier’s instruction. Quality of total
RNA was determined by using Bioanalyzer (UV spectrophotom-
eter Q3000, Quawell). Extracted RNA samples were stored at -
80uC until used.
For mRNA expression validation, we used 20 pair specimens (9
paired samples of adenocarcinomas and 11 paired samples of
squamous cell carcinomas of the lung. 12 pair were from the
previous 35 patient cohort.). In particular, There are 5 patients
whose ages are more than 60 and 15 patients who are younger
than 60 (17 male and 3 female). For the grade of differentiation, 11
and 9 are moderately differentiated and poorly differentiated,
respectively. For tumor stages, 19 patients are at T1-T2 and one is
at T3-T4. Lymph node metastases were found in 5 patients. For
the tumor stage, 9 patients have stage I and 11 patients have
higher stage tumors (Table S1).
Quantitative real-time PCR
10 ng of total RNA was reverse-transcribed using the TaqMan
miRNA reverse transcription kit and RT primers for miR-96 and
U6 snRNA (Applied Biosystems). The cDNAs were then analyzed
by real-time PCR using TaqMan probes for miR-96, and U6
snRNA (Applied Biosystems). We reverse transcribed three
micrograms of totalRNAtosingle-strandedcDNA using Fermentas
kit and then performed qRT-PCR experiments using SYBR Green
(RealMasterMix(SYBR Green), TIANGEN) on Applied Biosystems
7500 Real-Time PCR System. We analyzed gene expression using
2
DDCT method [66]. Relative expression of hsa-miR-96 was
determined in reference to an internal U6 snRNA control, and
relative mRNA expression was determined in reference to
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). We listed
the primer sequences that were used in mRNA expression
validation experiments in Table S12. In the statistical analysis, we
presented results as mean 6 SE, and assessed differences between
the groups by using paired or independent T-Test in SPSS 15.0.
Microarray hybridization
mRNA profiling were performed by using Illuminia Technol-
ogies ‘‘HumanHT-12 v4’’ according to manufacturer’s protocol.
miRNA profiling were performed by using Illuminia Technologies
‘‘humanMI_V2’’ according to the manufacturer’s protocol.
GenomeStudio 1.0 was used to perform average normalization
of the results from mRNA and miRNA microarrays. All data is
MIAME compliant and that the raw data has been deposited in a
MIAME compliant database. The expression data generated by
this study are available in the NCBI Gene Expression Omnibus
(GEO) as accession GSE29250.
Differential expression analysis
In each group-based comparison, we filtered out all miRNAs or
mRNAs that were not detected in any sample. Considering that
these samples may be too few to draw any reliable conclusions
about differential expression, we only chose genes that are
consistently up- or down-regulated in all the 6 NSCLC tissues
compared with the adjacent normal tissues as the differential
expression results. To get the significantly differential expression
results, the signal values were transformed (log2) and median
centered for each array, and then two-class paired differential
expression analysis was performed by using SAM (version 3.11;
Stanford University). Genes with significant differences were
selected at a FDR of 0.1.
miRNA target prediction and miRNA regulation value
We used three methods to predict miRNA targets. UTR
sequences were downloaded from the website of TargetScan. We
used perl scripts of TargetScan to predict targets. First, we
predicted targets with conserved miRNA binding sites using the
PCT method of TargetScan [33]. We then predicted all the
potential targets using TargetScan without considering sequence
conservation. At last, we run miRanda v3.3a on Linux platform as
Integrated RNA Analysis of NSCLC
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parameter settings.
We hypothesized that the average regulation value of a miRNA
is correlated with its expression level and the number of targets,
and can be calculated as: the expression value variation divided by
the number of expressed targets. During the process of cancer
development, some miRNAs may be up-regulated in cancer as
compared with the adjacent normal tissue, and in contrast, some
may be down-regulated, and therefore the regulation value will
become positive or negative respectively if the number of its
expressed targets is not changed significantly. For an mRNA, it
can be regulated by a variety of miRNAs, so the regulation value is
calculated by the addition of regulation value variations over all
variable miRNAs.
Supporting Information
Figure S1 Histological images of lung tumor tissues and the
adjacent normal lung tissues.
(TIF)
Figure S2 GO results of the 48 down-regulated conserved
targets of hsa-miR-96 (predicted using TargetScan).C
(TIF)
Figure S3 GO results of the anti-correlated genes (predicted
using TargetScan, and the conserved target sites were chosen).
(TIF)
Figure S4 Mature sequence alignment of hsa-miR-96 in
different species.
(TIF)
Figure S5 Different GO terms between the anti-correlated
group and the correlated group.
(TIF)
Table S1 Information for the 35 patients that were used in qRT-
PCR examination and the 6 patients that were used in performing
microarray.
(XLS)
Table S2 Up-regulated genes in NSCLC cancer tissue com-
pared with the adjacent normal tissue.
(XLS)
Table S3 Down-regulated genes in NSCLC cancer tissue
compared with the adjacent normal tissue.
(XLS)
Table S4 Up-regulated miRNAs in NSCLC cancer tissue
compared with the adjacent normal tissue.
(XLS)
Table S5 Down-regulated miRNAs in NSCLC cancer tissue
compared with the adjacent normal tissue.
(XLS)
Table S6 Target genes (predicted using PCT method of
TargetScan) which have conserved miRNA binding sites among
vertebrates or mannals.
(XLS)
Table S7 Target genes which have conserved miRNA binding
sites.
(XLS)
Table S8 All potential target genes that are predicted by
TargetScan.
(XLS)
Table S9 Regulation pattern based on all potential target genes
that are predicted by TargetScan.
(XLS)
Table S10 All potential target genes that are predicted by
miRanda.
(XLS)
Table S11 Regulation pattern based on all potential target genes
that are predicted by miRanda.
(XLS)
Table S12 Primer sequences for mRNA expression validation
experiments.
(XLS)
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